Michael Lauseker

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 22

Top Topics

Stem Cell Transplantation

Peripheral Blood

Chronic Myeloid Leukemia

Ejection Fraction

Top Venues

Biometrical journal. Biometrische Zeitschrift

American journal of hematology

European journal of haematology

This page only lists publications with an associated author ORCID identifier.

Publications

Annamaria Brioli, Elza Lomaia, Christian Fabisch, Tomasz Sacha, Hana Klamova, Elena Morozova, Aleksandra Golos, Philipp Ernst, Ulla Olsson-Stromberg, Daniela Zackova, Franck E Nicolini, Han Bao, Fausto Castagnetti, Elżbieta Patkowska, Jiri Mayer, Klaus Hirschbühl, Helena Podgornik, Edyta Paczkowska, Anne Parry, Thomas Ernst, Astghik Voskanyan, Elzbieta Szczepanek, Susanne Saussele, Georg-Nikolaus Franke, Alexander Kiani, Edgar Faber, Stefan W Krause, Luis Felipe Casado, Krzysztof Lewandowski, Matthias Eder, Peter Anhut, Justyna Gil, Thomas Südhoff, Holger Hebart, Sonja Heibl, Markus Pfirrmann, Andreas Hochhaus, Michael Lauseker
Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry. Leukemia 38 (5) (2024)
Rüdiger Hehlmann, Michael Lauseker
How to individualize therapy after failing milestones in chronic myeloid leukaemia: weighting late response and early death from CML against risk of alternative therapies. Leukemia 38 (2) (2024)
Annamaria Brioli, Elza Lomaia, Christian Fabisch, Tomasz Sacha, Hana Klamova, Elena Morozova, Aleksandra Golos, Philipp Ernst, Ulla Olsson-Stromberg, Daniela Zackova, Franck E Nicolini, Han Bao, Fausto Castagnetti, Elżbieta Patkowska, Jiri Mayer, Klaus Hirschbühl, Helena Podgornik, Edyta Paczkowska, Anne Parry, Thomas Ernst, Astghik Voskanyan, Elzbieta Szczepanek, Susanne Saussele, Georg-Nikolaus Franke, Alexander Kiani, Edgar Faber, Stefan W Krause, Luis Felipe Casado, Krzysztof Lewandowski, Matthias Eder, Peter Anhut, Justyna Gil, Thomas Südhoff, Holger Hebart, Sonja Heibl, Markus Pfirrmann, Andreas Hochhaus, Michael Lauseker
Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry. Leukemia 38 (5) (2024)
Rüdiger Hehlmann, Michael Lauseker
How to individualize therapy after failing milestones in chronic myeloid leukaemia: weighting late response and early death from CML against risk of alternative therapies. Leukemia 38 (2) (2024)
Rüdiger Hehlmann, Michael Lauseker
How to individualize therapy after failing milestones in chronic myeloid leukaemia: weighting late response and early death from CML against risk of alternative therapies. Leukemia 38 (2) (2024)
Rüdiger Hehlmann, Michael Lauseker
How to individualize therapy after failing milestones in chronic myeloid leukaemia: weighting late response and early death from CML against risk of alternative therapies. Leukemia 38 (2) (2024)
Annamaria Brioli, Elza Lomaia, Christian Fabisch, Tomasz Sacha, Hana Klamova, Elena Morozova, Aleksandra Golos, Philipp Ernst, Ulla Olsson-Stromberg, Daniela Zackova, Franck E Nicolini, Han Bao, Fausto Castagnetti, Elżbieta Patkowska, Jiri Mayer, Klaus Hirschbühl, Helena Podgornik, Edyta Paczkowska, Anne Parry, Thomas Ernst, Astghik Voskanyan, Elzbieta Szczepanek, Susanne Saussele, Georg-Nikolaus Franke, Alexander Kiani, Edgar Faber, Stefan W Krause, Luis Felipe Casado, Krzysztof Lewandowski, Matthias Eder, Peter Anhut, Justyna Gil, Thomas Südhoff, Holger Hebart, Sonja Heibl, Markus Pfirrmann, Andreas Hochhaus, Michael Lauseker
Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry. Leukemia 38 (5) (2024)
Rüdiger Hehlmann, Michael Lauseker
How to individualize therapy after failing milestones in chronic myeloid leukaemia: weighting late response and early death from CML against risk of alternative therapies. Leukemia 38 (2) (2024)
Annamaria Brioli, Elza Lomaia, Christian Fabisch, Tomasz Sacha, Hana Klamova, Elena Morozova, Aleksandra Golos, Philipp Ernst, Ulla Olsson-Stromberg, Daniela Zackova, Franck E Nicolini, Han Bao, Fausto Castagnetti, Elżbieta Patkowska, Jiri Mayer, Klaus Hirschbühl, Helena Podgornik, Edyta Paczkowska, Anne Parry, Thomas Ernst, Astghik Voskanyan, Elzbieta Szczepanek, Susanne Saussele, Georg-Nikolaus Franke, Alexander Kiani, Edgar Faber, Stefan W Krause, Luis Felipe Casado, Krzysztof Lewandowski, Matthias Eder, Peter Anhut, Justyna Gil, Thomas Südhoff, Holger Hebart, Sonja Heibl, Markus Pfirrmann, Andreas Hochhaus, Michael Lauseker
Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry. Leukemia (2024)
Annamaria Brioli, Elza Lomaia, Christian Fabisch, Tomasz Sacha, Hana Klamova, Elena Morozova, Aleksandra Golos, Philipp Ernst, Ulla Olsson-Stromberg, Daniela Zackova, Franck E Nicolini, Han Bao, Fausto Castagnetti, Elżbieta Patkowska, Jiri Mayer, Klaus Hirschbühl, Helena Podgornik, Edyta Paczkowska, Anne Parry, Thomas Ernst, Astghik Voskanyan, Elzbieta Szczepanek, Susanne Saussele, Georg-Nikolaus Franke, Alexander Kiani, Edgar Faber, Stefan W Krause, Luis Felipe Casado, Krzysztof Lewandowski, Matthias Eder, Peter Anhut, Justyna Gil, Thomas Südhoff, Holger Hebart, Sonja Heibl, Markus Pfirrmann, Andreas Hochhaus, Michael Lauseker
Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry. Leukemia 38 (5) (2024)
Rüdiger Hehlmann, Michael Lauseker
How to individualize therapy after failing milestones in chronic myeloid leukaemia: weighting late response and early death from CML against risk of alternative therapies. Leukemia 38 (2) (2024)
Rüdiger Hehlmann, Michael Lauseker
How to individualize therapy after failing milestones in chronic myeloid leukaemia: weighting late response and early death from CML against risk of alternative therapies. Leukemia (2024)
Michael Lauseker, Rüdiger Hehlmann, Andreas Hochhaus, Susanne Saussele
Survival with chronic myeloid leukaemia after failing milestones. Leukemia (2023)
Tobias Silzle, Sabine Blum, Annika Kasprzak, Kathrin Nachtkamp, Martina Rudelius, Barbara Hildebrandt, Katharina S Götze, Norbert Gattermann, Michael Lauseker, Ulrich Germing
The Absolute Monocyte Count at Diagnosis Affects Prognosis in Myelodysplastic Syndromes Independently of the IPSS-R Risk Score. Cancers 15 (14) (2023)
Rüdiger Hehlmann, Michael Lauseker, Astghik Voskanyan, Alice Fabarius, Claudia Haferlach, Andreas Hochhaus, Susanne Saussele
Impact of emerging ACA on survival in chronic myeloid leukemia (CML). Leukemia 36 (10) (2022)
Christina Rautenberg, Friedrich Stölzel, Christoph Röllig, Matthias Stelljes, Verena Gaidzik, Michael Lauseker, Oliver Kriege, Mareike Verbeek, Julia Marie Unglaub, Felicitas Thol, Stefan W Krause, Mathias Hänel, Charlotte Neuerburg, Vladan Vucinic, Christian-Friedrich Jehn, Julia Severmann, Maxi Wass, Lars Fransecky, Jens Chemnitz, Udo Holtick, Kerstin Schäfer-Eckart, Josephine Schröder, Sabrina Kraus, William Krüger, Ulrich Kaiser, Sebastian Scholl, Kathrin Koch, Lea Henning, Guido Kobbe, Rainer Haas, Nael Alakel, Maximilian-Alexander Röhnert, Katja Sockel, Maher Hanoun, Uwe Platzbecker, Tobias A W Holderried, Anke Morgner, Michael Heuser, Tim Sauer, Katharina S Götze, Eva Wagner-Drouet, Konstanze Döhner, Hartmut Döhner, Christoph Schliemann, Johannes Schetelig, Martin Bornhäuser, Ulrich Germing, Thomas Schroeder, Jan Moritz Middeke
Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia. Blood cancer journal 11 (10) (2021)
Christina Rautenberg, Michael Lauseker, Jennifer Kaivers, Paul Jäger, Carolin Fischermanns, Sabrina Pechtel, Rainer Haas, Guido Kobbe, Ulrich Germing, Thomas Schroeder
Prognostic impact of pretransplant measurable residual disease assessed by peripheral blood WT1-mRNA expression in patients with AML and MDS. European journal of haematology 107 (2) (2021)
Christina Rautenberg, Ulrich Germing, Stefanie Stepanow, Michael Lauseker, Karl Köhrer, Paul S Jäger, Stefanie Geyh, Min Fan, Rainer Haas, Guido Kobbe, Thomas Schroeder
Influence of somatic mutations and pretransplant strategies in patients allografted for myelodysplastic syndrome or secondary acute myeloid leukemia. American journal of hematology 96 (1) (2020)
Ruediger P Laubender, Ulrich Robert Mansmann, Michael Lauseker
Estimating the distribution of heterogeneous treatment effects from treatment responses and from a predictive biomarker in a parallel-group RCT: A structural model approach. Biometrical journal. Biometrische Zeitschrift 62 (3) (2020)
Michael Lauseker, Katharina Bachl, Anna Turkina, Edgar Faber, Witold Prejzner, Ulla Olsson-Strömberg, Michele Baccarani, Elza Lomaia, Daniela Zackova, Gert Ossenkoppele, Laimonas Griskevicius, Gabriele Schubert-Fritschle, Tomasz Sacha, Sonja Heibl, Perttu Koskenvesa, Andrija Bogdanovic, Richard E Clark, Joelle Guilhot, Verena S Hoffmann, Joerg Hasford, Andreas Hochhaus, Markus Pfirrmann
Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin. American journal of hematology 94 (11) (2019)
Michael Lauseker, Christine Zu Eulenburg
Analysis of cause of death: Competing risks or progressive illness-death model? Biometrical journal. Biometrische Zeitschrift 61 (2) (2019)
Michael Lauseker, Roman Gerlach, Wenke Worseg, Torsten Haferlach, Martin Tauscher, Joerg Hasford, Verena S Hoffmann
Differences in treatment and monitoring of chronic myeloid leukemia with regard to age, but not sex: Results from a population-based study. European journal of haematology 103 (4) (2019)